IntelGenx to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 30 2018 - 8:00AM
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the
“Company” or “IntelGenx”) today announced that its Chief Financial
Officer, Andre Godin, is scheduled to present at the Rodman &
Renshaw 20th Annual Global Investment Conference on
September 6, 2018 at 2:35 p.m. Eastern Time at the
St. Regis New York.
Mr. Godin will provide an overview
of IntelGenx's business during the presentation and will be
available to participate in one-on-one meetings with investors who
are registered to attend the conference.
The presentation will be webcast live and
archived for 90 days on the Company's
website, www.intelgenx.com, under "Investors".
About IntelGenx:
Established in 2003, IntelGenx is a leading oral
drug delivery company primarily focused on the development and
manufacturing of innovative pharmaceutical oral films based on its
proprietary VersaFilm™ technology platform.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility, established for the
VersaFilm™ technology platform, supports lab-scale to pilot and
commercial-scale production, offering full service capabilities to
its clients. More information about the company can be found at
www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking
information about IntelGenx's operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx's annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Each of the TSX Venture Exchange and OTCQX has
neither approved nor disapproved the contents of this press
release. Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Source: IntelGenx Technologies Corp.
For more information, please
contact:
Stephen KilmerInvestor Relations (514) 331-7440
ext 232stephen@intelgenx.com
Or
Andre Godin, CPA, CAExecutive Vice-President and
CFOIntelGenx Corp.(514) 331-7440 ext 203andre@intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Apr 2023 to Apr 2024